Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine versus other antidepressants for Burning Mouth Syndrome
ISRCTN13795228Phase 2Completed
- Sponsor
- University of Naples Federico II
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vortioxetine, paroxetine, sertraline, escitalopram and duloxetine in glossodynia (BMS) (5 arms), sponsored by University of Naples Federico II. Primary endpoints: Clinical remission or response at 6 and 12 months, Intra- and extra-oral examination and 7 more. Started Feb 2019; status: completed.
02
Drugs
vortioxetineparoxetinesertralineescitalopramduloxetine
03
Conditions
glossodynia (BMS)
Beyond the preview
Go deeper on ISRCTN13795228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13795228.